Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Cash Flow Reinvestment Rate
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow Reinvestment Rate of 0.94x as of December 2025, reinvesting CN¥270.12 Million (capex CN¥20.11 Million plus investments CN¥250.02 Million) from operating cash flow of CN¥287.81 Million. Explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) capital reinvestment to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Also explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year capital reinvestment analysis for Tianjin Lisheng Pharmaceutical Co Ltd. For live market cap and broader valuation context, see Tianjin Lisheng Pharmaceutical Co Ltd (002393) total market value.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | CN¥163.21 Million | CN¥451.85 Million | CN¥37.46 Million | ▼ -88.4% |
| 2024 | 3.13x | CN¥275.93 Million | CN¥88.26 Million | CN¥53.75 Million | ▲ +19.5% |
| 2023 | 2.62x | CN¥548.18 Million | CN¥209.51 Million | CN¥61.72 Million | ▲ +341.1% |
| 2022 | 0.59x | CN¥196.55 Million | CN¥331.38 Million | CN¥40.91 Million | ▼ -29.1% |
| 2021 | 0.84x | CN¥164.36 Million | CN¥196.34 Million | CN¥88.24 Million | ▼ -37.0% |
| 2020 | 1.33x | CN¥101.41 Million | CN¥76.37 Million | CN¥100.66 Million | ▲ +254.1% |
| 2019 | 0.37x | CN¥100.62 Million | CN¥268.33 Million | CN¥90.46 Million | ▼ -46.8% |
| 2018 | 0.70x | CN¥114.59 Million | CN¥162.69 Million | CN¥104.43 Million | ▲ +109.5% |
| 2017 | 0.34x | CN¥60.25 Million | CN¥179.25 Million | CN¥50.09 Million | ▼ -82.0% |
| 2016 | 1.86x | CN¥323.67 Million | CN¥173.60 Million | CN¥137.20 Million | ▲ +32.1% |
| 2015 | 1.41x | CN¥279.60 Million | CN¥198.13 Million | CN¥204.60 Million | ▼ -64.9% |
| 2014 | 4.02x | CN¥290.65 Million | CN¥72.24 Million | CN¥290.65 Million | ▲ +272.2% |
| 2013 | 1.08x | CN¥313.11 Million | CN¥289.62 Million | CN¥313.11 Million | ▲ +20.8% |
| 2012 | 0.89x | CN¥224.35 Million | CN¥250.72 Million | CN¥224.35 Million | ▼ -27.4% |
| 2011 | 1.23x | CN¥165.94 Million | CN¥134.58 Million | CN¥165.94 Million | ▲ +230.1% |
| 2010 | 0.37x | CN¥69.69 Million | CN¥186.55 Million | CN¥69.69 Million | ▲ +316.4% |
| 2009 | 0.09x | CN¥17.60 Million | CN¥196.14 Million | CN¥17.60 Million | ▼ -82.5% |
| 2008 | 0.51x | CN¥64.86 Million | CN¥126.59 Million | CN¥64.86 Million | ▲ +543.9% |
| 2007 | 0.08x | CN¥13.92 Million | CN¥174.94 Million | CN¥13.92 Million | — |